

# ***CD36* identified by weighted gene co-expression network analysis as a hub candidate gene in lupus nephritis**

Huiying Yang<sup>1</sup>, Hua Li<sup>Corresp. 1</sup>

<sup>1</sup> Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

Corresponding Author: Hua Li  
Email address: h\_li@zju.edu.cn

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), which often progresses to end-stage renal disease (ESRD) and ultimately leads to death. At present, there are no definitive therapies towards LN, so that illuminating the molecular mechanism behind the disease has become an urgent task for researchers. Bioinformatics has become a widely utilized method for exploring genes related to disease. This study set out to conduct weighted gene co-expression network analysis (WGCNA) and screen the hub gene of LN. We performed WGCNA on the microarray expression profile dataset of GSE104948 from Gene Expression Omnibus (GEO) database with 18 normal and 21 LN samples of glomerulus. A total of 5,942 genes were divided into 5 co-expression modules, one of which was significantly correlated to LN. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on the LN-related module and the module was proved to be associated mainly with the activation of inflammation, immune response, cytokines, and immune cells. Genes in the most significant GO terms were extracted for sub-networks of WGCNA. We evaluated the centrality of genes in the sub-networks by Maximal Clique Centrality (MCC) method and *CD36* was ultimately screened out as a hub candidate gene of the pathogenesis of LN. The result was verified by its differentially expressed level between normal and LN in GSE104948 and the other three multi-microarray datasets of GEO. Moreover, we further demonstrated that the expression level of *CD36* is related to the WHO Lupus Nephritis Class of LN patients with the help of Nephroseq database. The current study proposed *CD36* as a vital candidate gene in LN for the first time and *CD36* may perform as a brand-new biomarker or therapeutic target of LN in the future.

1  
2 **CD36 identified by weighted gene co-expression**  
3 **network analysis as a hub candidate gene in lupus**  
4 **nephritis**

5  
6  
7 Huiying Yang<sup>1</sup>, Hua Li<sup>1</sup>

8  
9 <sup>1</sup> Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of  
10 Medicine, Hangzhou, China

11  
12 Corresponding Author:

13 Hua Li

14 3 Qingchun East Road, Hangzhou, Zhejiang province, China

15 Email address: h\_li@zju.edu.cn  
16

17 **Abstract**

18 Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), which  
19 often progresses to end-stage renal disease (ESRD) and ultimately leads to death. At present,  
20 there are no definitive therapies towards LN, so that illuminating the molecular mechanism  
21 behind the disease has become an urgent task for researchers. Bioinformatics has become a  
22 widely utilized method for exploring genes related to disease. This study set out to conduct  
23 weighted gene co-expression network analysis (WGCNA) and screen the hub gene of LN. We  
24 performed WGCNA on the microarray expression profile dataset of GSE104948 from Gene  
25 Expression Omnibus (GEO) database with 18 normal and 21 LN samples of glomerulus. A total  
26 of 5,942 genes were divided into 5 co-expression modules, one of which was significantly  
27 correlated to LN. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)  
28 enrichment analyses were conducted on the LN-related module and the module was proved to be  
29 associated mainly with the activation of inflammation, immune response, cytokines, and immune  
30 cells. Genes in the most significant GO terms were extracted for sub-networks of WGCNA. We  
31 evaluated the centrality of genes in the sub-networks by Maximal Clique Centrality (MCC)  
32 method and *CD36* was ultimately screened out as a hub candidate gene of the pathogenesis of  
33 LN. The result was verified by its differentially expressed level between normal and LN in  
34 GSE104948 and the other three multi-microarray datasets of GEO. Moreover, we further  
35 demonstrated that the expression level of *CD36* is related to the WHO Lupus Nephritis Class of  
36 LN patients with the help of Nephroseq database. The current study proposed *CD36* as a vital  
37 candidate gene in LN for the first time and *CD36* may perform as a brand-new biomarker or  
38 therapeutic target of LN in the future.

## 39 Introduction

40 Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by  
41 autoantibody production, complement activation and immune complex deposition. The incidence  
42 of SLE ranges from 0.03‰ to 2.32‰ person-years worldwide (Rees et al. 2017).

43 Lupus nephritis (LN) is one of the most frequent and severe organ manifestations in patients with  
44 SLE, the hallmark of which is often glomerulonephritis. Approximately 50% of SLE patients  
45 develop clinically evident renal disease, up to 11% of whom develop end-stage renal disease  
46 (ESRD) at 5 years (Tektonidou, Dasgupta and Ward 2016, Almaani, Meara and Rovin 2017). LN  
47 is an important cause of ESRD and mortality. The initial and subsequent therapy of LN mainly  
48 consists of immunosuppressants and glucocorticoids, which means there are little efficient and  
49 specific therapies. Thus, it is a pressing task to clarify molecular mechanisms involved in LN.  
50 LN is characterized by its complicated physiopathologic mechanism. In LN patients, the  
51 formation of immune complexes in different glomerular compartments, the activation of innate  
52 immune signal pathways, the infiltration of immune cells and proinflammatory mediators can  
53 harm glomerular cells through various approaches (Devarapu et al. 2017). Although many  
54 studies have determined certain pathological mechanisms of LN, the pathogenesis is still far  
55 from clear.

56 With the development of gene microarray and high-throughput next-generation sequencing,  
57 bioinformatics analysis of gene expression profiling has been broadly applied to explore the  
58 mechanism underlying diseases and potential diagnostic biomarkers or treatment targets. Among  
59 diverse means aiming to investigate altered molecular elements based on comparison between  
60 groups of different states, weighted gene co-expression network analysis (WGCNA) is a  
61 powerful tool utilized for describing the correlation patterns among genes and exploring hub  
62 genes related to certain traits (van Dam et al. 2018, Langfelder and Horvath 2008). WGCNA  
63 constructs a co-expression network between genes, and then, genes are divided into several co-  
64 expression modules by clustering techniques. Genes in certain module are deemed to share  
65 similar biological function and biological process. At last, after relating modules to clinical traits,  
66 modules with high correlation to disease are further analyzed and hub genes of pivotal  
67 importance to disease are identified. WGCNA has been broadly used for studying of diseases  
68 such as cancer (Jardim-Perassi et al. 2019), neuropsychiatric disorder (Huggett and Stallings  
69 2019), chronic disease (Morrow et al. 2015) and proved to be quite useful.

70 However, although researchers have conducted numerous bioinformatics studies about LN and  
71 have got many achievements (Arazi et al. 2019, Panousis et al. 2019), WGCNA has rarely been  
72 used for studies of LN (Sun et al. 2019). In our study, we constructed a co-expression network of  
73 the expression profile of glomerulus tissue by WGCNA and confirmed gene modules related to  
74 LN. After systematically analyzing the LN-related co-expression module by series of  
75 bioinformatics methods, a hub gene associated with LN was identified and verified. Depend on  
76 the potential roles of the hub gene in the pathogenesis of LN, we expect to propose novel clues  
77 of the diagnosis and treatment of LN.

## 78 Materials & Methods

## 79 **Expression profile data collection**

80 The overall procedures of our study are illustrated in the flow chart (Fig. 1). The gene expression  
81 profile of GSE104948 was selected and obtained from the Gene Expression Omnibus (GEO)  
82 database (<https://www.ncbi.nlm.nih.gov/geo/>). The raw data is available in the GEO database.  
83 The dataset consists of microarray-based gene expression profiles of 32 LN samples and 18  
84 normal samples of glomerular tissues from SLE patients and living kidney transplant donors  
85 respectively. The glomerular tissues were microdissected and verified with glomerular-selective  
86 transcripts (Grayson et al. 2018). The expression values have already been log<sub>2</sub> transformed.

## 87 **Data preprocessing**

88 The probe annotation was conducted under the Perl environment with the microarray platform  
89 file. Probes matching with multiple genes were removed, and for genes corresponding to  
90 multiple probes, the average values of probes were regarded as the expression values of the  
91 genes. A total of 11,884 genes were left after the probe annotation.

92 Since non-varying genes are usually regarded as background noise, we filtered the genes by  
93 variance and the top 50% (5,942 genes) with larger variance were chosen for subsequent  
94 analyses.

## 95 **Weighted co-expression network construction and module division**

96 Before WGCNA, we excluded the outlier samples by sample clustering with the hierarchical  
97 clustering method. The sample IDs and details of all samples included in our study are available  
98 in Table. S1. After that, we applied WGCNA with the expression profile by using the WGCNA  
99 package (Langfelder and Horvath 2008) in the R environment (version 3.5.3). Firstly, we  
100 calculated the Pearson's correlation for all pair-wise genes and constructed a correlation matrix.  
101 Secondly, the correlation matrix was transformed to an adjacency matrix (also known as scale-  
102 free network) with an appropriate soft-thresholding value  $\beta$ . A reasonable  $\beta$  value would  
103 emphasize strong correlations between genes and penalize weak ones. We calculated the scale-  
104 free fit index and mean connectivity of each  $\beta$  value from 1 to 30 respectively, and when the  
105 scale-free fit index is up to 0.85, the  $\beta$  value with highest mean connectivity is deemed as the  
106 most appropriate one. Then, the adjacency matrix was converted to a topological overlap matrix  
107 (TOM) so that the indirect correlations between genes are concerned. Finally, we used average  
108 linkage hierarchical clustering according to the TOM-based dissimilarity measure to classify all  
109 genes into several co-expression modules with a minimum size of 30 genes, thereby the genes  
110 with similar expression patterns were divided into the same module. After defining the first  
111 principal component of a given module as eigengene, we calculated the Pearson's correlations of  
112 the eigengenes, and merged modules whose eigengenes were highly correlated (with Pearson's  
113 correlation higher than 0.75) into one module.

114 To verify the reliability of the division of modules, we plotted an adjacency heatmap of all the  
115 5,942 genes analyzed by WGCNA. Besides, we completed a cluster analysis of module  
116 eigengenes and plotted an adjacency heatmap to find out the interactions among modules.

## 117 **Identification of clinically significant modules**

118 The clinical traits of our samples included normal and LN, we calculated the correlation between  
119 modules and traits. Modules of positive correlation with LN were considered as playing roles in  
120 the pathogenesis of the disease. On the other hand, genes in modules of positive correlation with  
121 normal trait are indispensable for maintaining normal biological functions. Thus, we extracted  
122 gene modules of highest correlation with LN and normal for subsequent studies.

123 Here, we introduced the definition of gene significance (GS) and module membership (MM),  
124 which represent the correlation of a given gene with clinical trait and module eigengene  
125 respectively. Genes in clinical-related modules should have high values and preferable  
126 correlations of GS and MM.

### 127 **GO and KEGG pathway enrichment analyses**

128 To explore the involved signal pathways and biological characteristics of genes in clinical-  
129 related modules, we conducted Gene Ontology (GO) enrichment analysis and Kyoto  
130 Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and visualized the  
131 top 10 significant terms respectively with the clusterProfiler R package (Yu et al. 2012). For both  
132 of GO and KEGG, enrichment terms arrived the cut-off criterion of  $p$ -value  $< 0.01$  and  
133 Benjamin-Hochberg adjusted  $p$ -value  $< 0.01$  were considered as significant ones.

### 134 **Differentially expressed genes analysis**

135 To investigate the difference of the expression profiles between normal and LN samples of genes  
136 in clinical-related modules, we applied differentially expressed genes (DEGs) analysis based on  
137 Empirical Bayes test with the limma R package (Ritchie et al. 2015). The cut-off criterion was  
138 set as follow:  $|\log_2\text{fold change (logFC)}| > 1$ ;  $p$ -value  $< 0.01$ ; false discovery rate ( $FDR$ )  $< 0.001$ .  
139 The results were visualized with the heatmap R package (Galili et al. 2018).

### 140 **Identification of hub gene**

141 Hub gene of the LN-related module should have high connectivity with the whole module and  
142 LN trait, which may play critical roles in the molecular mechanism of LN. For identifying the  
143 hub gene related with LN, we extracted gene clusters that enriched in certain GO terms from the  
144 WGCNA network to construct sub-networks after GO enrichment analysis of the LN-related  
145 module. Then, we utilized the Cytoscape software and its plug-in cytohubba to seek out the hub  
146 gene from sub-networks (Shannon et al. 2003). After calculating the Maximal Clique Centrality  
147 (MCC) value of each gene, those with high MCC values was regarded as hub genes (Chin et al.  
148 2014). The results were exhibited with the Cytoscape software. We then surveyed the GS value,  
149 MM value and logFC value of the selected hub gene to validate its reasonability.

### 150 **Validation of hub gene with the other GEO datasets**

151 To further verify the differential expression level of the hub gene between normal and LN  
152 tissues, we analyzed the logFC value of the hub gene with data from the other three GEO  
153 datasets (GSE32591, GSE99339 and GSE113342). The GEO IDs and details of the datasets were  
154 given in Table. S1.

### 155 **Validation of the clinical significance of hub gene by Nephroseq database**

156 To assess the relationship between the expression level of the hub gene and the activity or grade  
157 of LN, we visited the Nephroseq database (<http://v5.nephroseq.org>), which provides unique

158 access to datasets from the Applied Systems Biology Core at the University of Michigan,  
159 incorporating clinical data which is often difficult to collect from public sources. We then  
160 analyzed the difference of the expression level of hub gene between patients in different WHO  
161 Lupus Nephritis Class (Weening et al. 2004) based on two datasets (the dataset of Peterson  
162 Lupus Glom and the dataset of Berthier Lupus Glom) from Nephroseq database (details available  
163 in Supplemental Document. 1). We performed unpaired t test for comparisons between groups  
164 and set the criterion of two-tailed value of  $p < 0.05$  as statistically significant.

## 165 **Results**

### 166 **Data preprocessing**

167 After data preprocessing, 5,942 genes were selected for subsequent analyses. Sample clustering  
168 excluded the outlier samples and a total of 18 normal samples and 21 LN samples were left. The  
169 final result of sample clustering is shown in Fig. 2A, revealing satisfactory intra-group  
170 consistency and distinct difference between groups. The GEO IDs and details about the source of  
171 the samples are available in Table. S1.

### 172 **Weighted co-expression network construction and module division**

173 In the current study, taking both scale-free fit index and mean connectivity as reference, the soft-  
174 thresholding was determined as 10 (Fig. 2B and Fig. 2C). Accordingly, the correlation matrix  
175 was transformed to an adjacency matrix and then converted to a topological overlap matrix.  
176 Based on average linkage hierarchical clustering and module merging, the genes were divided  
177 into 6 modules and were displayed with different colors (Fig. 3A), including the black, blue,  
178 brown, magenta, pink, and grey modules, containing 220, 2,881, 777, 465, 770, and 829 genes,  
179 respectively. Genes in the grey module were those couldn't be divided into any co-expression  
180 modules.

181 Fig. 3B depicts the topological overlap adjacency among all the 5,942 genes analyzed by  
182 WGCNA, indicating that most genes have higher correlation with genes in the same module and  
183 lower correlation with genes in other modules, which means the division of the modules was  
184 accurate. The clustering dendrogram and adjacency heatmap of eigengene are shown in Fig. 3C  
185 and Fig. 3D, meaning that the 5 modules were mainly separated into two clusters.

### 186 **Identification of clinically significant modules**

187 We calculated the module-trait correlation coefficients and showed the results in Fig. 4A. The  
188 results illuminated that the blue module displayed highest correlation with LN trait ( $r = 0.91$ ,  $p =$   
189  $2e-15$ ), while the brown module related best with normal trait ( $r = 0.66$ ,  $p = 4e-06$ ). The GS and  
190 MM value of all member genes of the blue and brown modules were shown in the scatterplots  
191 (Fig. 4B and Fig. 4C). The GS and MM value were of high correlation in the two modules (cor =  
192  $0.89$ ,  $p < 1e-200$ , and cor =  $0.73$ ,  $p = 3.1e-130$  respectively), suggesting that the genes in the two  
193 modules were associate with their module eigengenes and clinical traits synchronously and thus  
194 suitable for further analyses and hub gene excavation. We then renamed the two modules as top  
195 LN module and top non-LN module respectively.

### 196 **DEGs analysis of trait-related modules**

197 We applied DEGs analysis for the two trait-related modules. For the top LN module, 203 DEGs  
198 were screened in LN compare with normal, including 195 up-regulated genes and 8 down-  
199 regulated ones. While, the top non-LN module contained 78 DEGs, all of which were down-  
200 regulated. The top 30 of up-regulated and down-regulated genes are displayed in Fig. 5  
201 respectively. The logFC value,  $p$ -value, and  $FDR$  of DEGs are given in Table. S2.

### 202 **GO and KEGG Enrichment analyses of trait-related modules**

203 To confirm the biological themes of genes in the trait-related modules and find the underlying  
204 biological pathways behind LN, we performed GO and KEGG enrichment analyses towards the  
205 top LN and top non-LN modules and the top 10 significant terms of GO and KEGG are exhibited  
206 in Fig. 6 and Fig. 7 respectively. The complete results of GO and KEGG enrichment analyses  
207 were given in Table. S3.

208 For the top LN module, enriched GO-BP terms were mainly about activation of immune  
209 response, immune cells, cytokine production, and inflammation (Fig. 6A), such as “neutrophil  
210 activation” (gene count = 178,  $p = 7.26e-301.52E-20$ ), “positive regulation of defense response”  
211 (gene count = 160,  $p = 9.14e-25$ ), “activation of innate immune response” (gene count = 107,  $p =$   
212  $3.45e-18$ ). Enriched GO-MF terms were mainly about cytokine and their receptors (Fig. 6B),  
213 such as “cytokine binding” (gene count = 39,  $p = 2.47e-8$ ), “cytokine receptor activity” (gene  
214 count = 34,  $p = 5.3e-7$ ), “cytokine receptor binding” (gene count = 69,  $p = 2.98e-5$ ). For GO-CC,  
215 enriched terms were mainly involved in membrane and endocytic vesicle (Fig. 6C), such as  
216 “vesicle lumen” (gene count = 107,  $p = 4.13e-15$ ), “cytoplasmic vesicle lumen” (gene count =  
217 106,  $p = 8.99e-15$ ), “membrane region” (gene count = 95,  $p = 2.33e-12$ ). The results of KEGG  
218 enrichment were similar to that of GO-BP, were mainly about immune and inflammation (Fig.  
219 7A). The top KEGG terms included “Complement and coagulation cascades” (gene count = 31,  $p$   
220  $= 6.55e-6$ ), “Fc gamma R-mediated phagocytosis” (gene count = 34,  $p = 1.90e-5$ ), “Th1 and Th2  
221 cell differentiation” (gene count = 33,  $p = 3.05e-5$ ). Meanwhile, several well-known pathways  
222 involved in LN were also included, such as Th17 cell differentiation.

223 On the other hand, for the top non-LN module, the GO-BP results were mainly involved in the  
224 metabolism process of different kinds of molecule (Fig. 6D), for example, “small molecule  
225 catabolic process” (gene count = 93,  $p = 3.27e-41$ ), “organic acid catabolic process” (gene count  
226 = 73,  $p = 3.97e-39$ ), “carboxylic acid catabolic process” (gene count = 73,  $p = 3.97e-39$ ). The top  
227 10 terms of GO-MF and GO-CC are also displayed (Fig. 6E and Fig. 6F). Similarly, the top  
228 KEGG terms were mainly about metabolism process (Fig. 7B).

229 Besides, we found that the magenta module also had high correlation with LN trait. The results  
230 of enrichment analyses of magenta module are also given in Table. S3.

### 231 **Identification and validation of hub gene**

232 We extracted the genes enriched in two of the top 10 significant GO-BP terms in top LN module,  
233 namely “neutrophil activation” and “positive regulation of defense response”, and constructed  
234 two sub-networks of the weighted co-expression network respectively. Co-expression pairs with  
235 top 500 weighted correlations in the sub-networks were selected for hub gene excavation. After  
236 importing the gene co-expression pairs and their weighted correlations into Cytoscape, we

237 calculated the MCC value of genes and the most central genes of the sub-network were screened  
238 out as shown in Fig. 8. In both sub-networks, *CD36* had the maximum MCC value among all,  
239 and was therefore deemed as the hub gene under the pathogenesis of LN.

240 The GS and MM value of *CD36* were 0.772 and 0.833, revealing *CD36* was significant  
241 correlated with the top LN module and LN trait. The DEGs analysis showed that the expression  
242 level of *CD36* in LN was abnormally up-regulated compared with that of normal. The logFC of  
243 *CD36* was 2.298, which ranked 11th among all.

#### 244 **Validation of hub gene with the other GEO datasets**

245 For verifying our conclusion in a broader range, we interrogated the GEO database for more  
246 datasets about LN. We downloaded the datasets of GSE32591, GSE99339 and GSE113342, and  
247 then analyzed the differentially expressed level of *CD36* between LN and normal (Fig. 9). In the  
248 four different datasets, the expression level of *CD36* was consistently up-regulated in LN  
249 samples, illustrating a satisfactory reliability of the result.

#### 250 **Validation of hub gene by Nephroseq database**

251 We analyzed the expression level of *CD36* in glomerular tissues under different severity of LN  
252 evaluated by WHO Lupus Nephritis Class. The result indicates that *CD36* was significantly up-  
253 regulated with the aggravation of LN (Fig. 10), that is to say, *CD36* plays an important role in  
254 the development of LN.

#### 255 **Discussion**

256 In the current study, we used the expression profile of GSE104948 to screen the hub gene  
257 involved in the pathogenesis of LN. We performed WGCNA and divided all genes into 5 co-  
258 expression modules. After relating the modules to clinical traits, we concluded that the blue  
259 module was of highest correlation with LN and was suitable for hub gene excavating. The brown  
260 module had the highest correlation with normal trait, and was also worthy of subsequent  
261 analyses. GO and KEGG enrichment illuminated that genes in the top LN module were mostly  
262 enriched in biological themes of the activation of inflammation, immune response, cytokine, and  
263 immune cells, and the top non-LN module was mainly about the metabolism process of various  
264 molecules. What's more, DEGs analysis showed that almost all DEGs in top LN module were  
265 abnormally up-regulated, revealing an aberrant activated stage of inflammation and immune  
266 response in LN. On the other hand, all DEGs in the top non-LN module were down-regulated,  
267 meaning a reduced ability of material metabolism in LN. To achieve the ultimately purpose of  
268 finding out the hub gene, we extracted genes enriched in the GO terms of "neutrophil activation"  
269 and "positive regulation of defense response" and constructed sub-networks accordingly. Base  
270 on the MCC method, *CD36* with maximum value of MCC in both sub-networks was regarded as  
271 the hub gene behind the pathogenesis of LN. We investigated the GS, MM and logFC of *CD36*  
272 and validated its importance. We interrogated the GEO database and got more datasets of LN,  
273 the obvious overexpression of *CD36* was therefore further verified. Moreover, the association  
274 between *CD36* and WHO Lupus Nephritis Class showed directly that the expression level of  
275 *CD36* gradually up-regulates along with the development of LN evaluated by WHO Lupus



276 Nephritis Class, providing strong evidence that the abnormal over-expression of *CD36* is an  
277 important element in the pathogenesis of LN.

278 The *CD36* gene is located on band q11.2 of chromosome 7 (Fernandez-Ruiz et al. 1993). The  
279 protein encoded by *CD36* is a kind of transmembrane protein (also known as scavenger receptor  
280 B2) expresses on the surface of various kinds of cells. In the glomerulus of kidney, *CD36*  
281 expresses in podocyte (Hua et al. 2015), mesangial cells (Ruan et al. 1999) and interstitial  
282 macrophages (Kennedy et al. 2013). Meanwhile, *CD36* expresses in immunity correlating cells  
283 such as monocytes and macrophages (Collot-Teixeira et al. 2007). With multiple ligands, *CD36*  
284 involves in complex biological process such as lipid homeostasis, immune response and cell  
285 apoptosis.

286 There are no relative reports concerning the direct relationship between *CD36* and LN. Our  
287 results have shown that *CD36* mainly participates in the function of neutrophil, such as  
288 “neutrophil activation”, “neutrophil activation involved in immune response”, “neutrophil  
289 degranulation”, “neutrophil mediated immunity”, as well as the activation of immune response,  
290 such as “positive regulation of defense response”, “positive regulation of innate immune  
291 response”, “innate immune response-activating signal transduction”, “positive regulation of  
292 immune effector process”. Base on the results, we conclude that *CD36* performs important  
293 functions in the pathogenesis and development of LN through affecting the function of  
294 neutrophil and innate immune response. Studies have proved that deposited immune complexes  
295 (IC) could activate complement and attract neutrophils and potentiate their responses, which will  
296 lead to intense glomerulonephritis, release protease and Reactive Oxygen Species (ROS), and  
297 give rise to kidney involvement of SLE (Tsuboi et al. 2008). Besides, IC-induced activation of  
298 neutrophils can lead to the formation of neutrophil extracellular traps (NETs), which can be  
299 pathogenic and promote the release of type I interferon (Garcia-Romo et al. 2011). *CD36* may  
300 candidate in the pathogenesis of LN by the above-mentioned pathways.

301 Numerous studies have shown that *CD36* participates in the pathogenesis of several kinds of  
302 chronic kidney disease (CKD).

303 It has long been known that chronic inflammation is an important segment of the progression of  
304 CKD. Studies have proved that the ligands signal via *CD36* to promote inflammatory response  
305 and the recruitment and activation of macrophage in the glomerulus (Kennedy et al. 2013). A  
306 report of LN showed that renal macrophage is associated with onset of nephritis and indicates  
307 poor prognosis (Bethunaickan et al. 2011). Meanwhile, oxidant stress plays a critical role in  
308 glomerular dysfunction. Along with chronic inflammation, *CD36* may facilitate the development  
309 of oxidant stress in LN (Hua et al. 2015, Kennedy et al. 2013, Aliou et al. 2016).

310 Podocyte is most susceptible to injury among the component of the glomerulus and its injury  
311 leads to glomerular dysfunction in various renal diseases including LN. Here, we determined that  
312 podocyte functional markers were down-regulated in LN glomerular tissue, including *WT1*  
313 ( $\logFC = -0.273$ ,  $p = 0.009$ ) and *NPHS1* ( $\logFC = -0.306$ ,  $p = 0.034$ ), indicating the fact of  
314 podocyte injury. It is reported that in primary nephrotic syndrome mouse, the overexpression of

315 *CD36* in the podocyte promotes its apoptosis (Yang et al. 2018). There is probably similar  
316 pathogenesis in the progression of LN.  
317 Ectopic lipid deposition in kidney may cause lipotoxicity and further affect the function of the  
318 kidney (Lin et al. 2019). *CD36* is a multifunctional protein function as a key molecule in the  
319 uptake of long-chain fatty acids, which is the main component of fatty acids uptake system in the  
320 kidney and plays a critical rule in the development of CKD (Gai et al. 2019). The expression  
321 level of *CD36* is higher in kidney with acute or chronic damage, and lipid disorders will  
322 stimulate the up-regulation of *CD36*. Furthermore, *CD36* can promote the uptake of lipid from  
323 plasma to tissue (Hua et al. 2015, Lin et al. 2019, Nosadini and Tonolo 2011, Yang et al. 2017).  
324 Among our results, the top 10 GO terms of non-LN module includes two terms about lipid  
325 metabolism: fatty acid catabolic process ( $p = 8.03e-22$ ) and fatty acid metabolic process ( $p =$   
326  $2.62e-20$ ), implying that lipid disorders exist in the glomerular tissue, in which *CD36* may take  
327 part.  
328 Regrettably, as most reports on the relationship between *CD36* and kidney diseases are about the  
329 disorders of kidney in metabolic diseases, there is no study about the role *CD36* plays in immune  
330 response, which is worthy of further study in LN.

### 331 **Conclusions**

332 In conclusion, through WGCNA and a series of comprehensive bioinformatics analyses, *CD36*  
333 was confirmed for the first time as a hub gene in the pathogenesis of LN. *CD36* is likely to  
334 become a new biomarker or therapeutic target of LN. Our work might provide a new insight for  
335 exploring the molecular mechanisms of LN.

### 336 **References**

- 337 Aliou, Y., M. C. Liao, X. P. Zhao, S. Y. Chang, I. Chenier, J. R. Ingelfinger & S. L. Zhang  
338 (2016) Post-weaning high-fat diet accelerates kidney injury, but not hypertension programmed  
339 by maternal diabetes. *Pediatr Res*, 79, 416-24.
- 340 Arazi, A., D. A. Rao, C. C. Berthier, A. Davidson, Y. Liu, P. J. Hoover, A. Chicoine, T. M.  
341 Eisenhaure, A. H. Jonsson, S. Li, D. J. Lieb, F. Zhang, K. Slowikowski, E. P. Browne, A. Noma,  
342 D. Sutherby, S. Steelman, D. E. Smilek, P. Tosta, W. Apruzzese, E. Massarotti, M. Dall'Era, M.  
343 Park, D. L. Kamen, R. A. Furie, F. Payan-Schober, W. F. Pendergraft, 3rd, E. A. McInnis, J. P.  
344 Buyon, M. A. Petri, C. Putterman, K. C. Kalunian, E. S. Woodle, J. A. Lederer, D. A. Hildeman,  
345 C. Nusbaum, S. Raychaudhuri, M. Kretzler, J. H. Anolik, M. B. Brenner, D. Wofsy, N. Hachohen  
346 & B. Diamond (2019) The immune cell landscape in kidneys of patients with lupus nephritis.  
347 *Nat Immunol*, 20, 902-914.
- 348 Almaani, S., A. Meara & B. H. Rovin (2017) Update on Lupus Nephritis. *Clin J Am Soc*  
349 *Nephrol*, 12, 825-835.
- 350 Bethunaickan, R., C. C. Berthier, M. Ramanujam, R. Sahu, W. Zhang, Y. Sun, E. P. Bottinger, L.  
351 Ivashkiv, M. Kretzler & A. Davidson (2011) A unique hybrid renal mononuclear phagocyte  
352 activation phenotype in murine systemic lupus erythematosus nephritis. *J Immunol*, 186, 4994-  
353 5003.

- 354 Chin, C. H., S. H. Chen, H. H. Wu, C. W. Ho, M. T. Ko & C. Y. Lin (2014) cytoHubba:  
355 identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol*, 8 Suppl 4,  
356 S11.
- 357 Collot-Teixeira, S., J. Martin, C. McDermott-Roe, R. Poston & J. L. McGregor (2007) CD36 and  
358 macrophages in atherosclerosis. *Cardiovasc Res*, 75, 468-77.
- 359 Devarapu, S. K., G. Lorenz, O. P. Kulkarni, H. J. Anders & S. R. Mulay (2017) Cellular and  
360 Molecular Mechanisms of Autoimmunity and Lupus Nephritis. *Int Rev Cell Mol Biol*, 332, 43-  
361 154.
- 362 Fernandez-Ruiz, E., A. L. Armesilla, F. Sanchez-Madrid & M. A. Vega (1993) Gene encoding  
363 the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2.  
364 *Genomics*, 17, 759-61.
- 365 Gai, Z., T. Wang, M. Visentin, G. A. Kullak-Ublick, X. Fu & Z. Wang (2019) Lipid  
366 Accumulation and Chronic Kidney Disease. *Nutrients*, 11.
- 367 Galili, T., A. O'Callaghan, J. Sidi & C. Sievert (2018) heatmaply: an R package for creating  
368 interactive cluster heatmaps for online publishing. *Bioinformatics*, 34, 1600-1602.
- 369 Garcia-Romo, G. S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch,  
370 C. Guiducci, R. L. Coffman, F. J. Barrat, J. Banchemereau & V. Pascual (2011) Netting neutrophils  
371 are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci*  
372 *Transl Med*, 3, 73ra20
- 373 Grayson, P. C., S. Eddy, J. N. Taroni, Y. L. Lightfoot, L. Mariani, H. Parikh, M. T.  
374 Lindenmeyer, W. Ju, C. S. Greene, B. Godfrey, C. D. Cohen, J. Krischer, M. Kretzler & P. A.  
375 Merkel (2018) Metabolic pathways and immunometabolism in rare kidney diseases. *Ann Rheum*  
376 *Dis*, 77, 1226-1233.
- 377 Hua, W., H. Z. Huang, L. T. Tan, J. M. Wan, H. B. Gui, L. Zhao, X. Z. Ruan, X. M. Chen & X.  
378 G. Du (2015) CD36 Mediated Fatty Acid-Induced Podocyte Apoptosis via Oxidative Stress.  
379 *PLoS One*, 10, e0127507.
- 380 Huggett, S. B. & M. C. Stallings (2019) Cocaine'omics: Genome-wide and transcriptome-wide  
381 analyses provide biological insight into cocaine use and dependence. *Addict Biol*.
- 382 Jardim-Perassi, B. V., P. A. Alexandre, N. M. Sonehara, R. de Paula-Junior, O. Reis Junior, H.  
383 Fukumasu, R. Chammas, L. L. Coutinho & D. Zuccari (2019) RNA-Seq transcriptome analysis  
384 shows anti-tumor actions of melatonin in a breast cancer xenograft model. *Sci Rep*, 9, 966.
- 385 Kennedy, D. J., Y. Chen, W. Huang, J. Viterna, J. Liu, K. Westfall, J. Tian, D. J. Bartlett, W. H.  
386 Tang, Z. Xie, J. I. Shapiro & R. L. Silverstein (2013) CD36 and Na/K-ATPase-alpha1 form a  
387 proinflammatory signaling loop in kidney. *Hypertension*, 61, 216-24.
- 388 Langfelder, P. & S. Horvath (2008) WGCNA: an R package for weighted correlation network  
389 analysis. *BMC Bioinformatics*, 9, 559.
- 390 Lin, Y. C., M. S. Wu, Y. F. Lin, C. R. Chen, C. Y. Chen, C. J. Chen, C. C. Shen, K. C. Chen &  
391 C. C. Peng (2019) Nifedipine Modulates Renal Lipogenesis via the AMPK-SREBP  
392 Transcriptional Pathway. *Int J Mol Sci*, 20.

393 Morrow, J. D., W. Qiu, D. Chhabra, S. I. Rennard, P. Belloni, A. Belousov, S. G. Pillai & C. P.  
394 Hersh (2015) Identifying a gene expression signature of frequent COPD exacerbations in  
395 peripheral blood using network methods. *BMC Med Genomics*, 8, 1.

396 Nosadini, R. & G. Tonolo (2011) Role of oxidized low density lipoproteins and free fatty acids  
397 in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. *Nutr*  
398 *Metab Cardiovasc Dis*, 21, 79-85.

399 Panousis, N. I., G. K. Bertias, H. Ongen, I. Gergianaki, M. G. Tektonidou, M. Trachana, L.  
400 Romano-Palumbo, D. Bielser, C. Howald, C. Pamfil, A. Fanouriakis, D. Kosmara, A. Repa, P.  
401 Sidiropoulos, E. T. Dermitzakis & D. T. Boumpas (2019) Combined genetic and transcriptome  
402 analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. *Ann*  
403 *Rheum Dis*, 78, 1079-1089.

404 Rees, F., M. Doherty, M. J. Grainge, P. Lanyon & W. Zhang (2017) The worldwide incidence  
405 and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.  
406 *Rheumatology (Oxford)*, 56, 1945-1961.

407 Ritchie, M. E., B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi & G. K. Smyth (2015) limma  
408 powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic*  
409 *Acids Res*, 43, e47.

410 Ruan, X. Z., Z. Varghese, S. H. Powis & J. F. Moorhead (1999) Human mesangial cells express  
411 inducible macrophage scavenger receptor. *Kidney Int*, 56, 440-51.

412 Shannon, P., A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B.  
413 Schwikowski & T. Ideker (2003) Cytoscape: a software environment for integrated models of  
414 biomolecular interaction networks. *Genome Res*, 13, 2498-504.

415 Sun, G., P. Zhu, Y. Dai & W. Chen (2019) Bioinformatics Analysis of the Core Genes Related to  
416 Lupus Nephritis Through a Network and Pathway-Based Approach. *DNA Cell Biol*, 38, 639-  
417 650.

418 Tektonidou, M. G., A. Dasgupta & M. M. Ward (2016) Risk of End-Stage Renal Disease in  
419 Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.  
420 *Arthritis Rheumatol*, 68, 1432-41.

421 Tsuboi, N., K. Asano, M. Lauterbach & T. N. Mayadas (2008) Human neutrophil Fcγ3  
422 receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory  
423 diseases. *Immunity*, 28, 833-46.

424 van Dam, S., U. Vosa, A. van der Graaf, L. Franke & J. P. de Magalhaes (2018) Gene co-  
425 expression analysis for functional classification and gene-disease predictions. *Brief Bioinform*,  
426 19, 575-592.

427 Weening, J. J., V. D. D'Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers, G. B. Appel, J. E.  
428 Balow, J. A. Bruijn, T. Cook, F. Ferrario, A. B. Fogo, E. M. Ginzler, L. Hebert, G. Hill, P. Hill,  
429 J. C. Jennette, N. C. Kong, P. Lesavre, M. Lockshin, L. M. Looi, H. Makino, L. A. Moura & M.  
430 Nagata (2004) The classification of glomerulonephritis in systemic lupus erythematosus  
431 revisited. *J Am Soc Nephrol*, 15, 241-50.

432 Weening, J. J., V. D. D'Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers, G. B. Appel, J. E.  
433 Balow, J. A. Bruijn, T. Cook, F. Ferrario, A. B. Fogo, E. M. Ginzler, L. Hebert, G. Hill, P. Hill,  
434 J. C. Jennette, N. C. Kong, P. Lesavre, M. Lockshin, L. M. Looi, H. Makino, L. A. Moura & M.  
435 Nagata (2004) The classification of glomerulonephritis in systemic lupus erythematosus  
436 revisited. *J Am Soc Nephrol*, 15, 241-50.

437 Yang, X., D. M. Okamura, X. Lu, Y. Chen, J. Moorhead, Z. Varghese & X. Z. Ruan (2017)  
438 CD36 in chronic kidney disease: novel insights and therapeutic opportunities. *Nat Rev Nephrol*,  
439 13, 769-781.


440 Yang, X., Y. Wu, Q. Li, G. Zhang, M. Wang, H. Yang & Q. Li (2018) CD36 Promotes Podocyte  
441 Apoptosis by Activating the Pyrin Domain-Containing-3 (NLRP3) Inflammasome in Primary  
442 Nephrotic Syndrome. *Med Sci Monit*, 24, 6832-6839.

443 Yu, G., L. G. Wang, Y. Han & Q. Y. He (2012) clusterProfiler: an R package for comparing  
444 biological themes among gene clusters. *Omics*, 16, 284-7.

# Figure 1

Flow chart of the whole procedures in this study.




Data processing, analyses, hub gene identification and validation.



## Figure 2

Sample cluster dendrogram and soft-thresholding values ( $\beta$ ) estimation.

(A) Sample cluster dendrogram and clinical trait heatmap of 18 normal samples and 21 LN samples based on their expression profile. (B) Analysis of scale-free fit index of each  $\beta$  value from 1 to 30. (C) Analysis of mean connectivity of each  $\beta$  value from 1 to 30.  $\beta = 10$  was chosen for subsequent analyses as it has the biggest mean connectivity when the scale-free fit index is up to 0.85.






## Figure 3

Division and validation of co-expression modules.

(A) Dendrogram of all genes divided into 6 modules based on a dissimilarity measure (1-TOM). The modules labeled by color are indicated below the dendrogram. The upper part presents the original division by average linkage hierarchical clustering according to the TOM-based dissimilarity measure and the lower part presents the modules merged according to the Pearson's correlation of eigengenes. (B) Adjacency heatmap of the 5,942 genes analyzed by WGCNA. The depth of the red color indicates the correlation between all pair-wise genes. The red color mainly distributes in the diagonal of the heatmap. (C) Clustering dendrogram of eigengenes. (D) Adjacency heatmap of eigengenes. Red represented high adjacency (positive correlation) and blue represented low adjacency (negative correlation).




## Figure 4

Identification and verification of clinical related modules.


(A) Heatmap of module-trait correlations. Each cell depicts the correlation coefficients and  $P$ -value. The cells are colored by the intensity of correlation according to the color legend (red for positive correlation and blue for negative correlation). The blue module (top LN module) and brown module (top non-LN module) were identified as trait-related modules. (B) Scatter plot for correlation between the Gene significance (GS) and Module Membership (MM) in the top LN module. Correlation coefficients and  $P$ -value is labeled at the top. (C) Scatter plot for correlation between the GS and MM in the top non-LN module.

A


## Module-trait relationships



B

Module membership vs. gene significance  
cor=0.89, p<1e-200


C

Module membership vs. gene significance  
cor=0.73, p=3.1e-130

## Figure 5

DEGs analysis of two trait-related modules.


The color of each cell represents the expression level of a gene in a sample (red for high level and blue for low level). Only DEGs with top 30 logFC values are displayed. (A) Heatmap of DEGs in the top LN module. (B) Heatmap of DEGs in the top non-LN module.



## Figure 6

GO enrichment analyses of two trait-related modules.

The depth of color is corresponded to the enrichment significant of each term and the x-axis indicates the enriched gene count. (A) Top 10 significantly enriched GO Biological Process (BP) terms of top LN module. (B) Top 10 significantly enriched GO Molecular Function (MF) terms of top LN module. (C) Top 10 significantly enriched GO Cellular Component (CC) terms of top LN module. (D) Top 10 significantly enriched GO Biological Process (BP) terms of top non-LN module. (E) Top 10 significantly enriched GO Molecular Function (MF) terms of top non-LN module. (F) Top 10 significantly enriched GO Cellular Component (CC) terms of top non-LN module.





## Figure 7

KEGG enrichment analyses of two trait-related modules.

The depth of color is corresponded to the enrichment significant of each term and the size of the circle indicates the enriched gene count. (A) Top 10 significantly enriched KEGG terms of top LN module. (B) Top 10 significantly enriched KEGG terms of top non-LN module.






## Figure 8

Sub-networks of WGCNA based extracted based on most significant GO terms.


The nodes represent the genes and the edges represent the weighted correlation. Only co-expression pairs with top 500 weighted correlations are included. The red and yellow nodes represent genes of top 10 MCC values (red for a higher MCC value and yellow for lower). (A) Sub-network of the GO term “neutrophil activation”. (B) Sub-network of the GO term “positive regulation of defense response”.



## Figure 9

Differentially expressed level of *CD36* between LN and normal in different GEO datasets.

(A) Expression level of *CD36* in dataset of GSE104948. (B) Expression level of *CD36* in dataset of GSE32591. (C) Expression level of *CD36* in dataset of GSE99339. (D) Expression level of *CD36* in dataset of GSE113342.



## Figure 10

Differentially expressed level of *CD36* in glomerular tissues of different WHO Lupus Nephritis Class.

(A) Differentially expressed level of *CD36* in class II and class IV respectively (from the dataset of Berthier Lupus Glom). (B) Differentially expressed level of *CD36* in class III and class IV respectively (from the dataset of Peterson Lupus Glom).

